Abstract
Control of SARS-CoV-2 (SCV-2) transmission is a major priority that requires understanding SCV-2 replication dynamics. We developed and validated novel droplet digital PCR (ddPCR) assays to quantify SCV-2 subgenomic RNAs (sgRNAs), which are only produced during active viral replication, and discriminate them from full-length genomic RNAs (gRNAs) in a multiplexed format. We applied this multiplex ddPCR assay to 144 cross-sectional nasopharyngeal samples. sgRNAs were quantifiable across a range of qPCR cycle threshold (Ct) values and correlated with Ct values. The ratio of sgRNA:gRNA was remarkably stable across a wide range of Ct values, whereas adjusted amounts of N sgRNA to a human housekeeping gene declined with higher Ct values. Interestingly, adjusted sgRNA and gRNA amounts were quantifiable in culture-negative samples, although levels were significantly lower than in culture-positive samples. Longitudinal daily testing of 6 persons for up to 14 days revealed that sgRNA is concordant with culture results during the first week of infection but may be discordant with culture later in infection. Further, sgRNA:gRNA is constant during infection despite changes in viral culture. These data indicate stable viral transcription during infection. More work is needed to understand why cultures are negative despite persistence of viral RNAs.
Competing Interest Statement
YCM has received research grant support to Johns Hopkins University from Hologic, Ceres, Cepheid, Roche, ChemBio, Becton Dickinson, miDiagnostics, and Yukon, and has provided consultative support to Abbott. The other authors have declared that no conflict of interest exists.
Funding Statement
This work was supported by the HIV Prevention Trials Network (HPTN) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung and Blood Institute, National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS (UM1 AI068613); R01 AI138810 from NIAID (A.B. and C.T.), U5411090366 (YCM), U54EB007958-13 (YCM, MLR), U54EB007958-12S1 (YCM), and U54HL143541-02S2 (YCM, MLR, NG, CHL, AM, MC, RZ, CBB, HHM) under the NIH RADx-Tech program. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood Institute; the National Institutes of Health, or the U.S. Department of Health and Human Services. This work was also supported by the JHU COVID-19 Research and Response Program Fund, the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Discovery Program, and the Henry Jackson Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent was obtained from the participants in the UIUC cohort. The samples from JHCVL were completely anonymized, and thus could not be tracked to individual participants. This study was approved by the Johns Hopkins University IRB (IRB00254173 and IRB00272523) and Western IRB (20202884).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* share first co-authorship
↵^ share last co-authorship
Conflict of interest: YCM has received research grant support to Johns Hopkins University from Hologic, Ceres, Cepheid, Roche, ChemBio, Becton Dickinson, miDiagnostics, and Yukon, and has provided consultative support to Abbott. The other authors have declared that no conflict of interest exists.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.